Genmab A/S

NASDAQ:GMAB

Biotechnology

Healthcare
$50.97 -0.47%

-$0.12 today

Market cap
$31.43B
Beta
0.68
P/E (TTM)
18.7
EPS (TTM)
$13.36
52W Low $20.23High $35.43

Volume 2.96M

Average 1.85M

GMAB Other Current Assets

Current assets not reported separately, such as prepaid expenses.

Genmab A/SNASDAQ: GMAB

Other Current Assets · Q2 FY2026 · quarter ended Jun 2026

Other current assets remains negative

Q2 FY2026 other current assets was $0, compared with $0 a year earlier. Over 3 fiscal years it compounded at -99.7% a year.

Context

  • Other current assets amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
  • Other current assets increased in 1 of the last 3 fiscal years.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$3— YoY
Year agoJun 2025
$0— since
Other Current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR-99.7%——
5-year CAGR——
10-year CAGR——

Other Current Assets history

Mixed currencies · from the balance sheet

Latest · FY2025
3 USD
Year-over-year change
—

Other Current Assets vs competitors

How GMAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so other current assets is compared through growth and share of total assets rather than absolute size.
  • Other current assets amounts to 0.0% of total assets for GMAB, versus a peer median of 1.5%.
GMAB Competitors
Other Current Assets for GMAB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BNTXBioNTech SEJun 2026€5.21B EUR+2322.5%-8.1%25.6%
INCYIncyte CorporationJun 2026$91.94M USD-68.9%+23.9%1.2%
EXELExelixis, Inc.Jul 2026$48.1M USD-34.9%+6.7%1.9%
LEGNLegend Biotech CorporationSep 2026$10.1M USD+14328.6%+8.0%0.6%
ADCTADC Therapeutics S.A.Mar 2026$9.94M USD+38.4%+288.8%3.4%
MGNXMacroGenics, Inc.Mar 2026$8.37M USD+4.9%-4.9%3.8%
ALXOALX Oncology Holdings Inc.Mar 2026$5.24M USD—+5.8%2.9%
RCUSArcus Biosciences, Inc.Jun 2026$5M USD-66.7%-10.6%0.5%
GMABGenmab A/SJun 2026$0 USD—-99.7%0.0%
IOVAIovance Biotherapeutics, Inc.Sep 2026$0 USD-100.0%+16.8%0.0%
CGENCompugen Ltd.Mar 2026$0 USD——0.0%
Peer median (excluding GMAB) —-15.0%+6.7%1.5%

Competitors are the stored peer set for GMAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

Mixed currencies
Metric
FY2021
Dec 2021 · DKK
FY2022
Dec 2022 · DKK
FY2023
Dec 2023 · DKK
FY2024
Dec 2024 · DKK
FY2025
Dec 2025 · USD
Cash & Equivalents8.96B9.89B14.87B9.86B1.71B
Short-term Investments10.38B12.43B13.27B11.24B0
Net Receivables3.37B5.71B4.95B6.69B1.15B
Inventory0057M62M17.96M
Other Current Assets31M182M003
Total Current Assets22.74B28.22B33.14B27.85B2.88B
Property, Plant & Equipment (Net)975M1.32B1.64B263.83M279.36M
Goodwill0002.54B354.19M
Intangible Assets254M146M101M12.34B9.1B
Long-term Investments371M133M134M228M58.87M
Tax Assets00212M126.68M170.61M
Other Non-current Assets291M300M62M2.46B4
Total Non-current Assets1.89B1.9B2.15B17.96B9.97B
Total Assets24.63B30.12B35.29B45.81B12.84B
Account Payables350M0001.07B
Short-term Debt0000273M
Tax Payables0054M1.71B0
Deferred Revenue0033M24M23.95M
Other Current Liabilities860M1.75B00(663.92K)
Total Current Liabilities1.57B1.82B2.48B5.31B1.42B
Long-term Debt00005B
Deferred Tax Liabilities0002.36B363.17M
Deferred Revenue (Non-current)00480M480M94.78M
Other Non-current Liabilities500M491M35M30M5M
Total Non-current Liabilities863M1.01B1.2B3.81B5.59B
Total Liabilities2.43B2.84B3.68B9.11B7.01B
Common Stock66M66M66M66M9.98M
Retained Earnings10.02B14.81B19.02B23.55B4.09B
Accumulated OCI81M98M60M490M(180.59M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity22.2B27.28B31.61B36.7B5.83B
Total Debt425M597M770M1.03B5.43B
Net Debt(8.53B)(9.3B)(14.1B)(8.83B)3.71B

Genmab A/S

NASDAQ:GMAB

Intrinsic Alpha fair value

Locked

Current Price

$50.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.